What’s New in Psoriasis - 07/03/19
Résumé |
Psoriasis is a common, chronic inflammatory skin disease that is characterized by the formation of sharply demarcated, scaly, erythematous plaques. It affects about 2.2% of the population in the United States and has a large impact on patient quality of life. Many advances have been made in the last few years in the management of psoriasis. Proinflammatory cytokines play major roles in the pathogenesis of disease. Biologic medications targeting the aforementioned cytokines have been developed and studied for the management of psoriatic disease. This article summarizes the newest findings in the management of psoriasis and the various treatment options available.
Le texte complet de cet article est disponible en PDF.Keywords : Psoriasis, Treatment, Interleukin-23, Interleukin-17, TNF-α, Biologic
Plan
| Disclosure Statement: M. Lebwohl is an employee of Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Johnson & Johnson, Kadmon, MedImmune, AstraZeneca, Novartis, Pfizer, and ViDac, and is also a consultant for Allergan, Leopharma, and Promius. S. von Csiky-Sessoms has no conflicts of interest. |
Vol 37 - N° 2
P. 129-136 - avril 2019 Retour au numéro
Article précédent
- Therapeutic Hotline: The Latest and Greatest in Dermatology
- Seemal R. Desai
- What’s New in Hair Loss
- Leopoldo Duailibe Nogueira Santos, Jerry Shapiro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?